Osteocytes secrete paracrine factors that regulate the balance between bone formation and destruction. Among these molecules, sclerostin (encoded by the gene SOST) inhibits osteoblastic bone formation and is an osteoporosis drug target. The molecular mechanisms underlying SOST expression remain largely unexplored. Here, we report that histone deacetylase 5 (HDAC5) negatively regulates sclerostin levels in osteocytes in vitro and in vivo. HDAC5 shRNA increases, whereas HDAC5 overexpression decreases SOST expression in the novel murine Ocy454 osteocytic cell line. HDAC5 knockout mice show increased levels of SOST mRNA, more sclerostin-positive osteocytes, decreased Wnt activity, low trabecular bone density, and reduced bone formation by osteoblasts. In osteocytes, HDAC5 binds and inhibits the function of MEF2C, a crucial transcription factor for SOST expression. Using chromatin immunoprecipitation, we have mapped endogenous MEF2C binding in the SOST gene to a distal intergenic enhancer 45 kB downstream from the transcription start site. HDAC5 deficiency increases SOST enhancer MEF2C chromatin association and H3K27 acetylation and decreases recruitment of corepressors NCoR and HDAC3. HDAC5 associates with and regulates the transcriptional activity of this enhancer, suggesting direct regulation of SOST gene expression by HDAC5 in osteocytes. Finally, increased sclerostin production achieved by HDAC5 shRNA is abrogated by simultaneous knockdown of MEF2C, indicating that MEF2C is a major target of HDAC5 in osteocytes.
Introduction
O steocytes, the most abundant cell type in bone, are important regulators of bone remodeling by producing paracrine factors. (1) Osteocytes express receptor activator of NFkB ligand (RANKL), a crucial osteoclastogenic cytokine, (2, 3) and sclerostin (encoded by SOST), a potent inhibitor of canonical Wnt signaling, which decreases osteoblast number and activity. (4) In humans, lack of SOST owing to loss of function mutations causes high bone mass in the rare disease, sclerosteosis, (5) whereas reduced SOST levels owing to deletion of a downstream intergenic enhancer region causes a milder high bone mass phenotype in Van Buchem disease. (6) Common SOST polymorphisms are associated with bone density and fracture risk variation in the general human population. (7) Sclerostin antibodies are now under investigation for osteoporosis therapy. (8) Although regulation of SOST expression by parathyroid hormone (PTH) (9) (10) (11) and mechanical forces (12) (13) (14) (15) has been demonstrated, little is known about molecular mechanisms controlling its expression in osteocytes. The best-studied regulator of SOST expression in osteocytes is the transcription factor MEF2C. Presumably through binding to a downstream enhancer sequence in the intergenic region between SOST and its neighbor MEOX, MEF2C positively regulates SOST expression. (11) Mice lacking MEF2C in osteocytes, or lacking the downstream enhancer region, display reduced SOST levels and high bone mass. (16, 17) Histone deacetylases (HDACs) are a family of enzymes capable of deacetylating lysine residues in a wide variety of cellular proteins, including histones. (18) Class IIa HDACs (HDACs 4, 5, 7, and 9) contain N-terminal extensions with phosphoacceptor 14-3-3 binding sites that allow them to sense and transduce signaling information. (19) In addition, the N-termini of class IIa HDACs contain a MEF2-binding site that mediates repression of MEF2-driven gene expression. (20) Although roles for class IIa HDACs in osteoblasts have been described, (21) (22) (23) their functions in osteocytes remain largely unexplored. Recently, HDAC5 overexpression was reported to suppress SOST expression in luciferase assays in UMR106 cells. (24) We used loss of function analysis under physiologic conditions to ask whether class IIa HDACs might regulate MEF2C-driven SOST expression in osteocytes. We report that HDAC5 directly controls SOST expression and that mice lacking HDAC5 show increased sclerostin levels in osteocytes, low bone density, and reduced bone formation.
Materials and Methods

Germline HDAC5
À/À mice were provided by Dr. Eric Olson and studied at 8 weeks of age. Cell culture experiments were performed using a single-cell subclone of Ocy454 cells (Spatz and colleagues, manuscript in preparation, 2014). Lentiviral infections were performed using protocols available online (www.broadinstitute.org). Sclerostin ELISAs were performed using an antibody pair as described in Yu and colleagues. (25) See Supplemental Information for full details, and see Supplemental Fig. 6 for all PCR primer sequences used.
Results
We sought to establish an in vitro system to dissect mechanisms of SOST expression in osteocytes. Ocy454 cells are a conditionally immortalized cell line with many properties of bone-embedded osteocytes. The line was derived from bitransgenic mice for DMP1-GFP and a thermolabile SV40 large T antigen that is active at 33°C and inactive at 37°C (Spatz and colleagues, manuscript in preparation, 2014). Lentiviral (LV)-based shRNA-mediated gene silencing (26) (27) (28) was used to determine the roles of specific genes in regulating SOST expression. Supplemental Fig. S1A demonstrates that Ocy454 cells can be infected with a puromycinresistance-conferring LV expressing a control shRNA (shGFP) and retain sclerostin expression and its regulation by PTH.
We next used shRNA to reduce levels of known SOST-positive and -negative regulators, MEF2C (11, 16, 17) and Gsa, (29, 30) respectively. Gsa shRNA increased SOST expression and sclerostin secretion (Spatz and colleagues, manuscript in preparation, 2014). For MEF2C shRNA, the range of sclerostin expression was determined in each experiment using 8 to 10 control shRNAexpressing lentiviruses targeting nonexpressed genes (LacZ, luciferase, GFP, RFP). Dotted lines indicate two standard deviations above and below the mean value of sclerostin expression in the presence of control shRNAs. LV-mediated shRNA for MEF2C selectively reduced sclerostin secretion (Supplemental Fig. S1B ; each data point indicates a separate Mef2-targeting hairpin; data for MEF2B is not shown because MEF2B is not expressed in Ocy454 cells), and all the MEF2C-targeting shRNAs effectively reduced MEF2C protein levels (Supplemental Fig. S1C ).
A similar approach was then used to test the function of class IIa HDACs. As shown in Fig. 1A , infection with independent hairpins targeting HDAC5 (but not HDAC4, HDAC7, or HDAC9) increased sclerostin secretion across multiple experiments. For the HDAC5 shRNAs, individual hairpins are labeled next to the corresponding data points in Fig. 1A , B. The individual hairpins (F9 and F12) that best reduced HDAC5 mRNA and protein levels increased SOST expression (Fig. 1B and Supplemental Fig. S1D, E) . In contrast, HDAC4 and HDAC7 shRNAs comparably reduced target mRNA abundance but did not increase SOST (Fig. 1C, D) . HDAC9 is not expressed in Ocy454 cells (data not shown). Although the most effective HDAC4 and HDAC5 shRNAs reduced target mRNA by 60% to 70%, the "best" HDAC5 shRNA (F12) was more effective at reducing target protein levels than the corresponding "best" HDAC4 shRNA (D8) tested (Fig. 1E) . Although these data support a role for HDAC5 in controlling SOST expression, we cannot rule out a contribution from HDAC4 or HDAC7, given differences in protein knockdown. Because comparable results were found for two independent HDAC5 hairpins (F9 and F12; Fig. 1B, Supplemental Fig. S1D , and data not shown), the F12 hairpin was used for further study.
Stable HDAC5 (F12) shRNA-expressing Ocy454 subclones were then generated ( Fig. 2A) . These cells display growth kinetics (Fig. 2B ) comparable to that of control shLacZ-expressing cells. HDAC5 knockdown increases sclerostin secretion, particularly at earlier time points after cells are switched to the nonpermissive growth temperature (Fig. 2C ). Analysis of a panel of osteocytic genes over the course of differentiation revealed that HDAC5 knockdown targets a subset (SOST and DMP1 but not PHEX) of osteocyte markers (Fig. 2D) . Osteocytes express the key regulators of osteoclastogenesis, RANKL, and osteoprotegerin (OPG). (2, 3, 31) HDAC5 shRNA does not affect basal (Supplemental Fig. S2A, B) or PTH-stimulated (Fig. S2C ) expression of these factors.
LV overexpression was next used to increase HDAC5 (wildtype (WT) or S259/498A, a constitutively nuclear "superrepressor" version (32) levels in Ocy454 cells (Fig. 2E ). Although overexpression of either WT or S259/498A HDAC5 does not affect growth kinetics in Ocy454 cells (Fig. 2F) , overexpression of HDAC5, and especially of the S259/498A nuclear mutant form, reduces SOST expression and sclerostin secretion (Fig. 2G, H) .
To rule out off-target shRNA effects, HDAC5 shRNA cells were rescued with a human HDAC5 cDNA with several synonymous nucleotide changes in the murine shRNA targeting sequences (Fig. 2I ). As shown in Fig. 2J , HDAC5 cDNA rescue reduced sclerostin expression by HDAC5 shRNA cells, providing further evidence that the phenotype owing to HDAC5 (F12) shRNA is because of reduced HDAC5 protein levels.
To show that HDAC5 mRNA is expressed in osteocytes, HDAC5 mRNA levels were analyzed in primary DMP1-GFP neg (osteoblasts and stromal cells) and DMP1-GFP pos (enriched osteocytes) long bone cells isolated from DMP1-GFP mice. As previously reported, the GFP-negative fraction expresses high levels of the osteoblastspecific gene Keratocan, (33, 34) whereas SOST mRNA is exclusively detected in the GFP-positive fraction. As shown in Supplemental  Fig. S2D , HDAC5 mRNA is detected in both fractions, with slightly higher levels present in DMP1-GFP pos cells. To explore the role of HDAC5 in controlling sclerostin levels in vivo, global HDAC5-knockout (KO) mice were analyzed. These mice are normal appearing and fertile, with reported cardiac and behavioral phenotypes. (35, 36) Analysis of calvarial RNA from 8-week-old mice (n ¼ 12/group) demonstrates an 84% increase in SOST mRNA levels in the absence of HDAC5 (Fig. 3A) , with no changes in osteocyte density (Fig. 3B) . As previously described, (37) sclerostin immunoreactivity is largely confined to deeply embedded osteocytes relatively far from the endocortical surface in WT mouse tibias (Fig. 3C, left) . In contrast, many more sclerostin-positive osteocytes are close to the endocortical surface in HDAC5-KO sections (Fig. 3C, right) . The overall percentage of sclerostin-positive osteocytes is modestly increased in the absence of HDAC5 (Fig. 3D ). In contrast, the percentage of sclerostin-positive peri-endosteal osteocytes (defined as embedded osteocytes within the inner one-quarter of the cortical area) is dramatically increased in HDAC5 knockouts (Fig. 3E) .
We next investigated the functional consequences of increased osteocytic SOST expression in HDAC5-KO mice. Sclerostin is a Wnt pathway antagonist; (38, 39) therefore, we anticipated reduced activity of this pathway in HDAC5-KO mice. Wnt signaling promotes ß-catenin stabilization, (40) in part via inhibiting its N-terminal phosphorylation. (41) Immunostaining for the nonphosphorylated (active) form of ß-catenin revealed reduced staining in endosteal osteoblasts in the absence of HDAC5 (Fig. 4A, bottom) . Active ß-catenin levels were comparable between genotypes in primary spongiosa cells (Fig. 4A, top) , suggesting that reduced active ß-catenin in endosteal osteoblasts in the HDAC5-KO strain is a selective phenomenon that correlates with increased sclerostin at this skeletal site. AXIN2, a At all time points, the p value comparing control to shHDAC5 is <0.001, and the p value comparing control to shHDAC5 plus LV-HDAC5 is nonsignificant. For all panels, Ã p < 0.05.
canonical Wnt pathway target gene, (42) levels are reduced in HDAC5 KO bone RNA (Fig. 4B) .
To determine the role of HDAC5 in regulating (directly or indirectly) the expression of molecular markers of differentiation of various bone cell types, control and HDAC5-KO calvarial RNA was profiled for osteoblast (TNALP, BGLAP), osteoclast (ACP5, which encodes Trap5b), osteoclastogenic (TNFSF11 and TNFRSF11B encoding RANKL and OPG), and osteocyte (DMP1, PHEX) marker genes (Fig. 4C) . No obvious compensation at the mRNA level from the related class IIa HDACs 4 and 7 was observed. Although the expression of the majority of genes were unaffected, two significant differences were found. First, PHEX levels were increased in HDAC5-KO skull RNA. Second, osteocalcin (BGLAP) mRNA levels were decreased. This corresponds to reduced osteocalcin immunostaining in osteoblasts on the endosteal surface in HDAC5-KO mice (Fig. 4D) . Trabecular bone density in the distal femur of 8-week-old male and female wildtype and HDAC5 KO mice was quantified by mCT. A significant reduction in trabecular bone density was observed in HDAC5 KO mice (Fig. 4E, F and Supplemental Fig. S3) .
To determine the tissue-level consequences of HDAC5 knockout, we performed static and dynamic histomorphometry on tibias of 8-week-old female WT and HDAC5 KO mice. As previously reported, (23) trabecular bone volume (BV/TV) was approximately 40% lower in HDAC5-KO mice (Table 1) . This observation was supported by other structural trabecular bone parameters and all parameters showed highly significant differences. In addition, all dynamic parameters of bone formation were significantly reduced in HDAC5-KO mice, with a 40% reduction in mineral apposition rate (MAR) and a 50% reduction in bone-formation rate/bone surface (BFR/BS) ( Fig. 4G) , indicating a prominent defect in bone formation. These findings were further confirmed by analysis of cellular parameters, demonstrating reduced osteoblast number and surface per bone perimeter in HDAC5-KO mice. In contrast, osteoclastic parameters (osteoclast number and surface and eroded surface per bone perimeter) were not significantly changed by HDAC5 deficiency (Fig. 4H) , although there was a trend toward reduced osteoclast parameters. These findings are consistent with our model in which high sclerostin levels in HDAC5-KO mice cause blunted bone formation. Potential causes for the discrepant cellular data presented here and reported by Obri and colleagues (23) are addressed in the Discussion.
Having established that HDAC5 controls sclerostin levels in vitro and in vivo, we focused on the molecular mechanism(s) whereby this occurs. Because class IIa HDACs are known to regulate MEF2 function in many settings, (20) and MEF2C controls SOST expression in vivo (16, 17) and in Ocy454 cells (Supplemental Fig. S1B ), we asked whether HDAC5 could regulate MEF2C function in osteocytes. Endogenous MEF2C and HDAC5 proteins associate in Ocy454 cells ( Fig. 5A ; CREB and Sp1 are used as negative controls). A MEF2-driven reporter (43, 44) is more active in HDAC5 shRNA Ocy454 cells than in control LacZ shRNA cells ( Fig. 5B ; MEF2C shRNA serves as a positive control).
Several conserved noncoding sequences downstream of the SOST gene are present (45) in the region deleted in Van Buchem Disease ( Fig. 5C ; each number below the conservation plot corresponds to a different PCR primer set). When a region 45 kB downstream from the SOST transcription start site (termed ECR5 (11) by others and SOST'9' here) is deleted in vivo, SOST levels are reduced and high bone mass is observed. (17) Endogenous MEF2C association with the SOST gene has not been reported. We performed chromatin immunoprecipitation (ChIP) to determine MEF2C occupancy in Ocy454 cells cultured at 37°C for 14 days (a time point in which SOST expression is high). MEF2C chromatin association is found in the þ45 kB region amplified with primer set 9 (Fig. 5D) . Histone 3 lysine 27 acetylation (H3K27Ac, a mark of enhancer activity (46) ) is also found at this same region (Fig. 5E) . Because SOST expression is upregulated in Ocy454 cells over time at 37°C (Fig. 2C, H) , we asked whether temporal changes in chromatin dynamics might occur at the þ45 kB enhancer. As shown in Fig. 5F , SOST upregulation over time is accompanied by increased MEF2C, H3K27Ac, and p300 (another marker of active enhancers (47) ) occupancy at this genomic site.
Three lines of evidence support a direct role for HDAC5 in regulating MEF2C activity at the þ45 kB SOST enhancer over the course of osteocyte differentiation. First, HDAC5 shRNA causes increased activity of this element, but not of the proximal SOST promoter, in luciferase assays (Supplemental Fig. S4A, B) . MEF2C shRNA reduces the activity of this enhancer (Supplemental Fig. S4C ). Second, HDAC5 overexpression dose-dependently inhibits the activity of a MEF2-driven reporter from the desmin (Supplemental Fig. S4D ) and the SOST'9' (þ45 kB) enhancer (Supplemental Fig. S4E ). Third, endogenous HDAC5 association with this region in control (but not HDAC5 shRNA) Ocy454 cells can be detected by ChIP (Fig. 6A) . In addition to the þ45 kB enhancer site, HDAC5 associates with two other putative conserved enhancers with increased H3K27Ac levels. Moreover, HDAC5 þ45 kB SOST enhancer occupancy decreases over time at 37°C (Fig. 6B) , consistent with increased SOST expression. Although HDAC5 itself is a weak deacetylase, (48) it associates with the nuclear corepressor NCoR and the potent class I deacetylase HDAC3. (49, 50) Like HDAC5, endogenous NCoR and HDAC3 enhancer occupancy decrease as SOST expression increases (Fig. 6B) .
We next tested the functional consequences of HDAC5 shRNA on MEF2C binding and the presence of H3K27Ac at the SOST þ45 kB enhancer. Increased amounts of MEF2C and H3K27Ac are observed at this site, as well as two other conserved intergenic loci, in HDAC5 shRNA cells (Fig. 6C and Supplemental Fig. S5A, B) . HDAC5 S259/498A overexpression reduces region 9 H3K27Ac levels ( Fig. 6D and Supplemental Fig. S5C ). Consistent with its proposed role as a sequence-specific scaffolding protein to recruit corepressor complexes to genomic sites, (51) HDAC5 shRNA decreases NCoR and HDAC3 association with the SOST enhancer (Fig. 6E) .
Finally, we asked whether MEF2C is required for increased SOST production caused by HDAC5 shRNA. Ocy454 cells were infected with shRNA-expressing lentiviruses to knock down HDAC5, MEF2C, or both (Fig. 6F) . Reducing MEF2C levels in the setting of HDAC5 shRNA decreased sclerostin secretion, indicating that MEF2C is required for the ability of HDAC5 shRNA to increase SOST (Fig. 6G, H) . This confirms our model that HDAC5 knockdown causes a MEF2C gain of function phenotype that drives high sclerostin production.
Discussion
Our data indicate that HDAC5 functions as a negative regulator of MEF2C-dependent SOST expression in osteocytes. This maps (at least in part) to the distal enhancer 45 kB downstream from the SOST transcription start site identified by Leupin, Collette, and Loots and colleagues. (11, 17, 45) Based on our results, we propose a model (Fig. 7) in which early in osteocyte differentiation, HDAC5 recruits the corepressors NCoR and HDAC3 to the SOST þ45 kB enhancer, thus suppressing SOST expression. As osteocyte differentiation occurs, HDAC5 occupancy is reduced, allowing increased binding of MEF2C along with the coactivator p300, which increases H3K27Ac and the ability of this enhancer to promote high levels of SOST expression. Future studies are required to elucidate the signals upstream of HDAC5 during osteocyte differentiation. Additionally, at this point we do not know if HDAC5 functions as a deacetylase or a scaffolding/ adaptor protein in osteocytes.
Multiple possible roles for HDAC5 in bone cells have been proposed. (24, (52) (53) (54) (55) Because HDAC5 is absent in all cells in the HDAC5 knockout mice, we cannot conclude that the skeletal phenotype we observe is solely because of direct actions of HDAC5 in osteocytes. Here, we report that mice lacking HDAC5 in (D, E) ChIP for MEF2C (D) and H3K27Ac (E) was performed after culture of Ocy454 cells for 14 days at 37°C. (F) ChIP-qPCR using primer set 9 (þ45 kB SOST enhancer) for MEF2C, H3K27Ac, and p300 over the course of Ocy454 cell differentiation. For all three antibodies, significantly (p < 0.01) increased enrichment was noted at day 15 compared with day 1. For all panels, error bars represent triplicate biological repeats. For all panels, Ã p < 0.01. The p value for primer set 9 comparing shLuc and shHDAC5 for H3 K27Ac ChIP is 0.00018. (E) ChIP was performed for NCoR and HDAC3 on control (shLuciferase) and HDAC5 shRNA Ocy454 cells after 3 days in culture at 37°C. qPCR was then performed for the SOST þ45 kB enhancer using primer pair 9. The p value for NCoR comparing shLuc and shHDAC5 is 0.00231; the p value for HDAC3 comparing shLuc and shHDAC5 is 0.00418. all cells are osteopenic, with high SOST expression and reduced bone formation. In contrast, Obri and colleagues (23) recently reported that HDAC5 functions in osteoblasts to control MEF2C-driven RANKL expression, with increased RANKL in HDAC5-KO mice causing osteopenia owing to high osteoclastic activity. Here, we did not observe a role for HDAC5 in controlling RANKL levels in vitro (Supplemental Fig. S2A -C) or in vivo (Fig. 4C) . Furthermore, our histomorphometric analysis (in which TRAPstained osteoclasts were scored in a blinded manner) revealed normal osteoclast numbers in the HDAC5 knockout mouse (Table 1 and Fig. 4H ). The same HDAC5-null strain (35) was employed for both the current study and the study of Obri and colleagues. Possibilities to explain these discordant results include differences in genetic background, sex (we analyzed females, whereas Obri and colleagues analyzed males), or skeletal site (we analyzed tibia, whereas Obri and colleagues mainly focused on vertebra). We should note that transgenic mice overexpressing sclerostin in bone are not reported to have increased osteoclastic activity. (45, 56) Proof that the osteopenia and reduced osteoblast activity is attributable in part to elevated sclerostin levels will require treatment of HDAC5-deficient mice with, for example, a neutralizing sclerostin antibody.
Sclerostin levels in peri-endosteal osteocytes are increased in the absence of HDAC5 (Fig. 3C, E) , and this correlates with reduced non-phospho beta-catenin staining in nearby endosteal osteoblasts (Fig. 4A) . However, we observe decreased trabecular bone volume fraction (Fig. 4E, F) but normal cortical thickness (Supplemental Fig. S3 ). Quantification of sclerostin levels in cancellous osteocytes is more challenging than in cortical osteocytes, so at this time we cannot correlate this trabecular osteopenia with increased trabecular SOST levels. The absence of a cortical bone phenotype in 8-week-old mice is not entirely unexpected: Transgenic mice overexpressing SOST in bone show trabecular osteopenia but normal cortical thickness. (45, 56) Class IIa HDAC function is controlled by nucleo-cytoplasmic shuttling through dynamic phosphorylation and 14-3-3 binding. In other cell types, N-terminal phosphorylation leads to 14-3-3 association and cytoplasmic retention. (20, 44, 57) A number of extracellular signals regulate osteocytic SOST expression. (39, 58) Recently, it was shown that PTH stimulates HDAC5 dephosphorylation, nuclear translocation, and SOST enhancer binding using overexpression in UMR106 cells. (24) The functional significance of this pathway in osteocytes in vivo remains unknown. Inhibiting HDAC5 N-terminal kinases may be of therapeutic benefit to reduce SOST expression by osteocytes.
The accelerated expression pattern of sclerostin secretion in vitro in HDAC5 shRNA cells (Fig. 2B) is consistent with our in vivo immunostaining results (Fig. 3B) . Sclerostin is considered a marker of "late"/"mature" osteocytes, (59, 60) and it is possible that deeply embedded osteocytes are also more "mature" than their peri-endosteal counterparts. An alternative hypothesis is that differential mechanical forces or differences in the extracellular cytokine milieu on peri-endosteal versus deep osteocytes in vivo account for differences in sclerostin expression in these cells. We currently do not know if HDAC5 controls aspects of osteoblast to osteocyte conversion in vivo, as has been demonstrated for Gsa. (29) Although our data suggest a direct role for HDAC5 in regulating SOST expression, we cannot rule out indirect effects on osteocyte biology, illustrated by changes in DMP1 (Fig. 2C) or PHEX (Fig. 4A) found in its absence.
GWAS data indicate that an intronic HDAC5 SNP (rs228769) is associated with variations in bone mineral density (BMD). (61) Single-nucleotide polymorphisms (SNPs) in MEF2C and SOST also control BMD, (61, 62) suggesting the importance of the MEF2C/ HDAC5/SOST pathway in humans. A cluster of BMD-regulating SNPs in SOST maps to the human orthologous region to the mouse þ45 kB enhancer. (63) The effects of these sequence variants on MEF2C or HDAC5 binding remains unexplored. In conclusion, here we show that HDAC5, a gene associated with BMD variation in humans, is a direct negative regulator of MEF2C-driven sclerostin expression in osteocytes, both in vitro and in vivo.
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